Pediatric Langerhans Cell Histiocytosis with Liver Involvement, 453 Patients

A retrospective clinical study of 453 children with Langerhans cell histiocytosis (LCH) treated at a single hospital in Egypt between 2007 and 2021. The dataset, authored by Seham Hassan and shared under a CC-BY-4.0 license, focuses on 80 patients with hepatic involvement to identify structural and functional prognostic indicators. It includes data on liver function, hepatomegaly Z-scores, treatment response, and survival outcomes.

Use Cases

• Predicting treatment failure based on the presence of hepatic dysfunction at diagnosis.
• Modeling 5-year overall survival (OS) and event-free survival (EFS) using baseline biochemical factors like hypoalbuminemia.
• Assessing the prognostic value of week 6 treatment response for long-term outcomes.
• Comparing risk stratification models that emphasize liver function versus liver size (hepatomegaly).

Strengths

• Includes data from 453 pediatric patients over a 14-year period (2007-2021).
• Focuses on a specific cohort of 80 patients with hepatic involvement, allowing for detailed analysis.
• Reports specific statistical measures, such as hazard ratios and odds ratios, for key prognostic factors.

Limitations

• Row count and column-level documentation are unknown, which limits suitability assessment.
• Data is from a single center (Children’s Cancer Hospital, Egypt), which may limit generalizability.
• The primary data file is a 137.5 KB DOCX document, suggesting the underlying dataset may be small or embedded in a report.

Provenance

Source

Children’s Cancer Hospital, Egypt.

Collection Method

Retrospective clinical study.

Time Range

2007 to 2021

Freshness

Last updated 2026-05-29 04:53:26.

Geography

Egypt